Srikanth Krishnamurthy

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trial

P. Frith, K. Kostikas, P. Olsson, 2018, Respirology.

Parental Atopy and Exposure to Pets on Asthma: A Hospital-Based Case-Control Study

A. Mathew, S. Ramalingam, R. David, 2011, International journal of preventive medicine.

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Evgeny V. Morozov, V. G. Abramov, T. Welte, 2022, Infection.

Is serum cholesterol a risk factor for asthma?

Karthikeyan Ramaraju, Srikanth Krishnamurthy, Smrithi Maamidi, 2012, Lung India : official organ of Indian Chest Society.

Drug-resistant tuberculosis – A ticking time bomb!

Srikanth Krishnamurthy, 2018, Perspectives in clinical research.

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

S. Salvi, R. Kodgule, Saiprasad Patil, 2021, ERJ Open Research.

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

S. Salvi, R. Kodgule, Saiprasad Patil, 2022, Lung India : official organ of Indian Chest Society.